A previous report described a case of post-COVID-19 myelitis that presented with acute myelopathic symptoms, in which the diagnosis was established on the basis of responsiveness to immunotherapy and the presence of anti-ACE2 antibodies, despite cerebrospinal fluid analysis revealing only mild protein elevation (32). This evidence concerns the gene ACE2 and COVID-19.